KRAS Target Evaluation Report

This KRAS target evaluation report is generated based on structured data from PatSnap Target & Disease MCP and PatSnap Clinical Trials MCP. The target biology and disease context come from PatSnap Target & Disease MCP. The clinical competition and trial evidence come from PatSnap Clinical Trials MCP. The goal is to show how an AI agent can turn structured life sciences intelligence into a target evaluation report that is easier to scan, compare, and act on.

KRAS target evaluation dashboard

Target	KRAS / GTPase KRas	Overall view	High attractiveness, but only for differentiated programs
UniProt	P01116	HGNC	6407
Direct drug count	270	Roll-up drug count	759
Development-stage drugs	217	Development-stage roll-up	632
Associated diseases	106	Disease roll-up	142
MCP data source	Target & Disease MCP	Target reference	target:d9ded8f23b4140a5828314a55d2d66b4

One-screen recommendation

Enter	Non-G12C alleles, active-state RAS inhibition, resistance-defined populations, CNS activity, or rational combinations.
Partner	Combination-enabling programs where clinical trial density already shows strong momentum, especially CRC combinations with EGFR antibodies.
Monitor	KRYSTAL-4, KRYSTAL-10, CodeBreaK 300, CodeBreaK 301, and next-generation KRAS G12C / pan-KRAS programs.
Avoid	Undifferentiated KRAS G12C follow-on programs without clear potency, safety, brain-metastasis, resistance, or combination advantages.

Biology module: why KRAS is attractive

PatSnap Target & Disease MCP identifies KRAS as a Homo sapiens target with the approved symbol KRAS and UniProt ID P01116. The target profile describes KRAS as a signal transducer in the Ras-MAPK pathway that regulates cell proliferation and survival. Ras proteins bind GDP/GTP and have intrinsic GTPase activity. The profile also links KRAS biology to colorectal cancer mechanisms, including transcriptional silencing of tumor suppressor genes in CRC cells.

Biology signal	Evidence from MCP target profile	R&D implication
Pathway centrality	Ras-MAPK signaling, proliferation, survival	Strong causal biology, but many feedback loops
Target tractability	Large drug and development-drug counts in MCP data	Validated tractability, high crowding
Disease breadth	106 associated diseases, 142 roll-up diseases	Broad opportunity, but indication prioritization matters
Translational anchor	Published protein-function references in the target record	Supports target rationale and mechanistic storytelling

Disease-context module

Disease	MCP disease profile	Development-drug signal	Why it matters for KRAS
Non-Small Cell Lung Cancer	A heterogeneous group including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma, treated collectively because of shared treatment strategy.	1,525 direct development drugs; 2,151 roll-up	Core KRAS G12C market with multiple active clinical strategies.
Colorectal Cancer	Tumors or cancer of the colon, rectum, or both.	1,544 direct development drugs; 2,422 roll-up	Combination strategy is central, especially KRAS G12C plus EGFR-directed therapy.

Clinical competition module: focused MCP trial counts

Drug	Indication query	Matched registered trials	Interpretation
Sotorasib	Non-small cell lung cancer	37	Established KRAS G12C clinical footprint with ongoing combination and real-world studies.
Adagrasib	Non-small cell lung cancer	19	Competitive NSCLC activity including Phase 3 first-line combination studies.
Sotorasib	Colorectal cancer	5	More focused CRC landscape, with Phase 3 combination studies shaping evidence.
Adagrasib	Colorectal cancer	8	CRC strategy emphasizes combinations such as cetuximab-based regimens.

Selected trial landscape from Clinical Trials MCP

Program / study	Phase	Status	Strategic read
Adagrasib plus pembrolizumab plus chemotherapy vs placebo plus pembrolizumab plus chemotherapy in previously untreated non-squamous NSCLC with KRAS G12C mutation (KRYSTAL-4)	Phase 3	Recruiting	Shows competition moving into first-line NSCLC combination positioning.
Study of sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb in treatment-naive metastatic CRC with KRAS p.G12C mutation (CodeBreaK 301)	Phase 3	Recruiting	Highlights CRC combination pressure and first-line ambition.
Sotorasib and panitumumab vs investigator's choice for participants with KRAS p.G12C mutation (CodeBreaK 300)	Phase 3	Completed	Demonstrates mature CRC combination validation logic.
Phase 3 study of MRTX849 with cetuximab vs chemotherapy in advanced CRC with KRAS G12C mutation (KRYSTAL-10)	Phase 3	Active, not recruiting	Confirms adagrasib's CRC competitive lane.
Adagrasib plus SRS for KRAS G12C-mutated NSCLC with untreated brain metastases	Phase 2	Recruiting	Points to CNS and brain-metastasis differentiation as an opportunity area.

Result evidence module

Drug query	Published / indexed result records	Examples returned by Clinical Trials MCP
Sotorasib	87	Real-world outcomes in KRAS G12C-mutated metastatic NSCLC; intracranial effectiveness in brain metastases; ctDNA dynamics after targeted therapy.
Adagrasib	41	Adagrasib plus cetuximab / combination studies; real-world comparison with sotorasib; KRAS G12C advanced solid tumor results.

Attractiveness scorecard

Dimension	Score	Why
Biology rationale	5 / 5	KRAS is positioned in Ras-MAPK signaling and regulates proliferation and survival.
Human / clinical validation	5 / 5	Multiple KRAS G12C drugs, Phase 3 studies, and published result records.
Clinical momentum	5 / 5	Focused MCP queries show 37 sotorasib NSCLC trials and 19 adagrasib NSCLC trials.
Competitive whitespace	2 / 5	G12C is crowded; whitespace is stronger in non-G12C alleles, CNS, resistance, and combinations.
IP and differentiation burden	2 / 5	High density around first-wave G12C inhibitors and combination claims.
Overall	High, selective	Attractive for differentiated biology and clinical strategy, unattractive for undifferentiated follow-ons.

Clinical development map

Lane	Opportunity	Risk	Action
KRAS G12C NSCLC	Validated commercial and clinical path	High crowding, strong benchmarks	Enter only with measurable differentiation
KRAS G12C CRC	Combination logic remains important	EGFR feedback and regimen complexity	Prioritize rational combinations and biomarkers
Non-G12C alleles	Larger whitespace	Higher technical risk	Invest where allele biology and safety window are clear
Pan-KRAS / RAS(ON)	Broad opportunity across tumor types	Therapeutic index and resistance uncertainty	Build translational package early
CNS / brain metastases	Specific differentiation angle in NSCLC	Clinical design and endpoint complexity	Monitor Phase 2 signals and design CNS-enabled assets

How MCP changes the workflow

Traditional target report	MCP-enabled agent workflow
Analyst manually searches target databases, disease databases, and trial registries separately.	Agent calls Target & Disease MCP and Clinical Trials MCP inside one reasoning workflow.
Evidence is copied into slides or docs with limited traceability.	Each data block can preserve MCP-derived references such as target, disease, trial, and result IDs.
Reports are hard to refresh when trial status changes.	The same prompt can be rerun to refresh clinical competition and result evidence.

Start building target evaluation agents with PatSnap Life Sciences MCP Servers

Data note: target and disease modules were generated from PatSnap Target & Disease MCP. Clinical trial counts, selected trials, and result-record counts were generated from PatSnap Clinical Trials MCP. This article is for research and competitive intelligence purposes and is not medical, legal, regulatory, or investment advice.

KRAS Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy